Mineralys Therapeutics

Public

Radnor, PennsylvaniaHealthcarewww.mineralystx.com

Mineralys Therapeutics is now publicly traded

The data on this page reflects Mineralys Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.

Went Public

Feb 9, 2023

Last Round

Follow-on Offering

Sep 4, 2025

Total Funding Raised

$786.3M

Company Overview

Mineralys (NAS: MLYS) is a biopharmaceutical company focused on developing innovative treatments for diseases associated with elevated aldosterone levels, including its lead product candidate, lorundrostat, an oral selective aldosterone synthase inhibitor aimed at managing uncontrolled and resistant hypertension.

Sector

Healthcare

AI Layer

Non-AI

Keywords

oral aldosterone synthase inhibitor (ASI)uncontrolled and resistant hypertension therapyhighly selective aldosterone synthase inhibitordysregulated aldosterone disease treatmenttargeted hypertension therapycortisol-sparing hypertension drugcardiorenal condition therapyhypertension drug developmentmineralocorticoid receptor antagonist (MRA) alternativechronic kidney disease (CKD) therapyobstructive sleep apnea therapy

Mineralys Therapeutics Comparables

Compare Mineralys Therapeutics with similar companies based on industry and business-model similarity.

Mineralys Therapeutics comparables — related companies by embedding similarity
Company	Similarity	Market Cap
Retension Pharmaceuticals	78%

View all Comparables

Mineralys Therapeutics Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Follow-on Offering	Sep 4, 2025
Private Placement	Feb 8, 2024
IPO	Feb 9, 2023
Series B	Jun 8, 2022
Series A	Apr 6, 2021

View all Funding Rounds

Mineralys Therapeutics Investors

Notable investors and investment history

Mineralys Therapeutics investors
Investor	Rounds
Evercore ISI	IPO, Follow-on Offering
HealthCor Partners Management	Series B
RA Capital Management	IPO, Series B, Private Placement
TCG Crossover	Private Placement
Guggenheim Securities	IPO
Phase4 Partners	Series B
Andera Partners	Series B

View all Investors

Mineralys Therapeutics Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Mineralys Therapeutics Filings

SEC and related filings with document metadata.

Firmographic Details

HeadquartersRadnor, Pennsylvania

Employee Range126

Year Founded2020

Last FundingSep 4, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.